RPCA
QNCX icon

Running Point Capital Advisors’s Quince Therapeutics QNCX Stock Holding History

Running Point Capital Advisors’s Portfolio QNCX Stock Details QNCX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-16
Closed -$292K – 155
2021
Q3 		$292K Buy
+16
New +$254K 0.13% 84

Other funds holding QNCX

ECG
EPIQ Capital Group San Francisco, California $383M AUM 46.87% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Running Point Capital Advisors's QNCX Position: Q4 2021 in Review

Running Point Capital Advisors sold out of Quince Therapeutics (QNCX) in Q4 2021, closing a stake of 16 shares — an estimated $292K sold.

Running Point Capital Advisors first reported a position in QNCX in Q3 2021 and held it in 1 quarter. The position peaked at $292K in Q3 2021. 97 funds tracked by Wall St. Rank hold QNCX as of Q4 2021.

  • Running Point Capital Advisors reported no remaining Quince Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Running Point Capital Advisors sold 16 Quince Therapeutics shares in Q4 2021, an estimated $292K.
  • Running Point Capital Advisors first reported a position in Quince Therapeutics in Q3 2021 and held it in 1 quarter.
  • Running Point Capital Advisors's Quince Therapeutics position peaked at $292K in Q3 2021.
  • 97 funds tracked by Wall St. Rank held Quince Therapeutics as of Q4 2021.

Based on Running Point Capital Advisors's 13F filing for Q4 2021, filed 10 Feb 2022.